China Pharma EV/EBIT CPHI

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 9.2×; Mar 2020
Peer median: 3.7×

China Pharma has no meaningful EV/EBIT today: it made an operating loss of $4.4M over the last twelve months.

It was last meaningful in Mar 2020, at 9.2×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	9.2×	4.6×	12.1×
2019	4.2×	1.8×	10.9×
2018	1.7×	1.6×	2.6×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	62.7×	0.4×	67.9×
2012	0.4×	0.3×	0.8×

Against its peers

Companies in Drug Manufacturers - General nearest China Pharma's size, closest first, today.

Company	EV/EBIT
CPHIChina Pharma	n/m
ATNMActinium Pharmaceuticals	1.2×
SPROSpero Therapeutics	2.1×
LFVNLifevantage	9.6×
NATRNatures Sunshine Products	5.2×
Peer median	3.7×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on China Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.